About This EventSionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing ...

Jennifer Fitzpatrick, directrice juridique de Sionna Therapeutics, a vendu le 5 décembre 2025 un total de 10 250 actions de ...

28/11 Un administrateur de Sionna Therapeutics cède des actions pour 4,8 millions de dollars, selon un dépôt auprès de la SEC MT 19/11 SIONNA THERAPEUTICS, INC. : Opinion positive de BTIG ZM 05/11 ...

As of Monday, December 01, Sionna Therapeutics, Inc.’s SION share price has dipped by 11.58%, which has investors questioning if this is right time to buy.

WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...

Sionna Therapeutics, Inc. ( (SION)) has released its Q3 earnings. Here is a breakdown of the information Sionna Therapeutics, Inc. presented to its investors. Sionna Therapeutics, Inc. is a ...

Sionna Therapeutics reported a narrowed GAAP EPS loss and maintains a strong $325M cash position, funding operations through 2028. SION advanced its cystic fibrosis pipeline, launching Phase 2a for ...

Investing.com - Raymond James has reiterated its Strong Buy rating and $45.00 price target on Sionna Therapeutics (NASDAQ:SION) following the company’s third-quarter 2025 update. The $45 target ...

(MENAFN- GlobeNewsWire - Nasdaq) Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis ...

Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug ...